Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice

BACKGROUND: Lenvatinib monotherapy was approved in the United States for first‐line treatment of patients with unresectable hepatocellular carcinoma (uHCC) in 2018. This study assessed real‐world treatment patterns and outcomes of lenvatinib beyond first‐line systemic treatment in the United States....

Descripción completa

Detalles Bibliográficos
Autores principales: Singal, Amit G., Nagar, Saurabh P., Hitchens, Abby, Davis, Keith L., Iyer, Shrividya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875657/
https://www.ncbi.nlm.nih.gov/pubmed/35822407
http://dx.doi.org/10.1002/cnr2.1679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875657/
https://www.ncbi.nlm.nih.gov/pubmed/35822407
http://dx.doi.org/10.1002/cnr2.1679

Ejemplares similares